Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25530401 | 1.00 | SIGMAR1 (0.33) | SIGMAR1ACHEPHGDHMGLLCARM1 | |
| SCHEMBL18501202 | 0.82 | GBA1 (0.39) | — | |
| SCHEMBL12942165 | 0.79 | — | — | |
| SCHEMBL10196493 | 0.79 | — | — | |
| SCHEMBL12942170 | 0.79 | — | — | |
| SCHEMBL23828685 | 0.79 | CXCR4 (0.33) | SIGMAR1ACHEPHGDHMGLLCARM1 | |
| SCHEMBL16924597 | 0.79 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL27634533 | 0.79 | GBA2 (0.42) | — | |
| SCHEMBL23467522 | 0.77 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL5284935 | 0.77 | GNAI3 (0.33) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20130150366-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA, INTELLECTUAL PROPERTY (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150366-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, CFTR | SIGMAR1 1465/4885ACHE 796/4885PHGDH 323/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | SIGMAR1 4480/4885ACHE 4805/4885PHGDH 890/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | SIGMAR1 4480/4885ACHE 4805/4885PHGDH 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.